Recent Updates
Recently added Catalysts
ORGO Positive Sentiment

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023

Monday, April 10, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Organogenesis Holdings Inc. announced that it will report its first quarter financial results for fiscal year 2023 after the market closes on May 10, 2023. The company, which specializes in regenerative medicine solutions for advanced wound care and surgical markets, will also host a conference call at 5:00 p.m. Eastern Time to discuss the results and provide updates. Stakeholders are encouraged to participate in the call and access the live webcast available on the company's website.
Price reaction · baseline $2.18 (2023-04-06 close) · clean, no other ORGO news in the window
day 0 close · peak
-2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Organogenesis is a leading company in regenerative medicine.
  • The upcoming financial report may indicate positive growth.
  • Management will provide a corporate update, showcasing transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~4 mo
High dilution risk
Lead asset
Amniotic Allograft
Phase 3 · Knee Osteoarthritis

Full Press Release Details

CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2023 financial results will be reported after the market closes on Wednesday, May 10th.
Management will host a conference call at 5:00 p.m. Eastern Time on May 10th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.

Frequently Asked Questions

When will Organogenesis report Q1 2023 financial results?

Organogenesis will report its Q1 2023 financial results on May 10th after market close.

What time is the conference call for Q1 results?

The conference call discussing Q1 results is scheduled for 5:00 p.m. ET on May 10th.

How can I access the conference call?

Participants can access the conference call via a live webcast or teleconference link.

Where can I find the archived webcast?

The archived webcast will be available on the company's website for about one year.

What markets does Organogenesis focus on?

Organogenesis specializes in advanced wound care, surgical, and sports medicine markets.

ShareAdd on Google
Tags: ORGO Viatris Investor Conferences Healthcare Organogenesis regenerative medicine financial results wound care surgical medicine
Last updated: Apr 10, 2023

Biotech snapshot

Cash runway
$47M liquidity · $11M/mo burn
~4 mo
High dilution risk
Lead asset
Amniotic AllograftPhase 3
Knee Osteoarthritis →